Overview

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Status:
COMPLETED

Trial end date:
2023-11-14

Target enrollment:

Participant gender:

Summary

The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an injection device in non-Japanese participants.

Phase:

PHASE1

Details

Lead Sponsor:

Amgen

Treatments:

teprotumumab